| Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. | |
| | |
MedLine Citation:
|
PMID: 9738648 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Nitric oxide, synthesized from L-arginine by nitric oxide synthase (NOS), is a vasodilator and inhibits vascular smooth muscle cell (SMC) proliferation and migration. The effects of local NOS gene transfer on restenosis after experimental balloon angioplasty were investigated. METHODS AND RESULTS: Left anterior descending coronary artery angioplasty was performed in 25 pigs. Animals received an intramural injection of adenovirus (1.5 x 10(9) pfu) carrying either the NOS cDNA (AdCMVceNOS) or no cDNA (AdRR5) via the Infiltrator. Local gene transfer efficiency and bioactivity of recombinant protein were assessed after 4 days. Indices of restenosis were evaluated by computerized planimetry on coronary artery sections prepared 28 days after angioplasty. Adenoviral vectors permitted efficient gene delivery to medial SMCs and adventitial cells of coronary arteries. Vascular cGMP levels were depressed after angioplasty from 1.30+/-0.42 to 0.33+/-0.20 pmol/mg protein (P<0.05) but were restored after constitutive endothelial (ce) NOS gene transfer to 1.82+/-0.98 pmol/mg (P<0.05 versus injured group and P=NS versus control). The ratio of the neointimal area to the internal elastic lamina fracture length, maximal neointimal thickness, and percent stenosis were all reduced in AdCMVceNOS- versus AdRR5-transduced pigs (0.59+/-0.14 versus 0.80+/-0.19 mm, P=0.02; 0.75+/-0.21 versus 1.04+/-0.25 mm, P=0.019; and 53+/-15% versus 75+/-11%, P=0.006, respectively). Lumen area was significantly larger (0.70+/-0.35 mm2 in AdCMVceNOS versus 0.32+/-0.18 mm2 in AdRR5, P=0.007). CONCLUSIONS: Percutaneous adenovirus-mediated NOS gene transfer resulted in efficient local overexpression of functional NOS after angioplasty in coronary arteries. Restored NO production in injured coronary arteries significantly reduced luminal narrowing, most likely through a combined effect on neointima formation and on vessel remodeling after angioplasty. |
| | |
Authors:
|
O Varenne; S Pislaru; H Gillijns; N Van Pelt; R D Gerard; P Zoldhelyi; F Van de Werf; D Collen; S P Janssens |
Related Documents
:
|
8668298 - Percutaneous rotational coronary atherectomy: initial green lane and mercy hospitals' e... 3155558 - Efficacy of percutaneous transluminal coronary angioplasty compared with single-vessel ... 2521538 - Benefit of the perfusion catheter for emergency coronary artery grafting after failed p... 16521638 - Transradial primary angioplasty and stenting in indian patients with acute myocardial i... 9504868 - Clinical comparison of 180-degree and 360-degree data collection of technetium 99m sest... 20059668 - Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. |
Journal Detail:
|
Title: Circulation Volume: 98 ISSN: 0009-7322 ISO Abbreviation: Circulation Publication Date: 1998 Sep |
Date Detail:
|
Created Date: 1998-09-24 Completed Date: 1998-09-24 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 919-26 Citation Subset: AIM; IM |
Affiliation:
|
Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenoviridae* Angioplasty, Transluminal, Percutaneous Coronary / adverse effects* Animals Coronary Vessels / enzymology, injuries*, physiopathology Cyclic GMP / metabolism Gene Expression Gene Transfer Techniques* Genes, Reporter Muscle, Smooth, Vascular / enzymology Myocardial Ischemia / therapy Nitric Oxide / metabolism Nitric Oxide Synthase / genetics* Nitric Oxide Synthase Type III Recurrence Swine Transgenes / genetics Tunica Intima / enzymology beta-Galactosidase / genetics |
| Chemical | |
Reg. No./Substance:
|
10102-43-9/Nitric Oxide; 7665-99-8/Cyclic GMP; EC 1.14.13.39/Nitric Oxide Synthase; EC 1.14.13.39/Nitric Oxide Synthase Type III; EC 3.2.1.23/beta-Galactosidase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Noninvasive, in utero imaging of mouse embryonic heart development with 40-MHz echocardiography.
Next Document: Tumor-induced immune dysfunction: the macrophage connection.